MedWatch

MedWatch launched in 1993 as FDA's single-doorway reporting and safety-communication system for FDA-regulated medical products. Reports concern adverse events, product-quality problems, therapeutic failures, medication errors, counterfeit suspicion, and use-related issues for drugs, biologics, medical devices, special nutritional products, cosmetics and dietary supplements.

• Form FDA 3500 — voluntary, used by healthcare professionals, patients, caregivers and consumers. Free-text-friendly. Direct path into FAERS, MAUDE or CAERS.
• Form FDA 3500A — mandatory for manufacturers, importers and (for devices) user facilities. Structured fields, clock-driven submission deadlines, distinct routes per product type.
• Form FDA 3500B — consumer-friendly version of 3500, simpler language.

Both feed FDA's product-specific databases — FAERS for drugs/biologics, MAUDE for devices, CAERS for foods/cosmetics/dietary supplements — and are increasingly exposed via public dashboards (openFDA) for industry and researcher use.

21 CFR Part 803 sets the device adverse-event reporting framework that uses MedWatch 3500A as the data carrier:

• Manufacturers — report within 30 calendar days of becoming aware of information that reasonably suggests a device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur.
• Manufacturers — 5-working-day report when the event necessitates remedial action to prevent unreasonable risk of substantial harm to public health, or when FDA has requested it.
• Importers — report deaths and serious injuries within 30 days to FDA and the manufacturer; malfunctions to the manufacturer only.
• User facilities (hospitals, nursing homes, ambulatory-surgery centres, outpatient diagnostic/treatment facilities) — death to FDA and manufacturer within 10 working days; serious injury to manufacturer within 10 working days (or to FDA if the manufacturer is unknown).

FDA's eMDR system is the required electronic submission gateway; paper submissions have not been the default for many years and are accepted only on case-by-case waiver.

• 21 CFR 314.80 (drugs) and 21 CFR 600.80 (biologics) — manufacturers submit 15-day Alert Reports for serious + unexpected adverse drug experiences within 15 calendar days of receipt, followed by periodic reports (PADER for drugs at the FDA-set schedule; PSURs for biologics on the global cycle).
• Submissions are made via FDA Adverse Event Reporting System (FAERS) using ICH E2B(R3) electronic format; MedWatch 3500A serves as the human-readable form.
• Serious-and-unexpected events are differentiated from serious-and-listed; both must be reported but the clocks and follow-up obligations differ.

The Dietary Supplement and Nonprescription Drug Consumer Protection Act requires manufacturers, packers and distributors whose name appears on the label of a dietary supplement to report serious adverse events within 15 business days of receipt, with follow-up information as it becomes available. Reports are submitted via MedWatch 3500A and feed CAERS.

• Death or life-threatening event.
• Hospitalisation (initial or prolonged).
• Disability or permanent damage.
• Congenital anomaly / birth defect.
• Required intervention to prevent permanent impairment or damage.
• Other serious important medical events.
• Product-quality problems (contamination, packaging, labelling defects, suspected counterfeit, sub-potency, super-potency, stability failure).
• Therapeutic failure where the product did not work as intended.
• Medication errors that reached the patient.

1. Receive — capture every complaint at first contact (call centre, sales rep, website, social media, distributor).
2. Triage — within 24-48 hours classify as adverse-event-only, product-quality-only, or both; assess seriousness against the regulatory definitions.
3. Decide reportability — for each FDA jurisdiction the product touches (drug, biologic, device, supplement, cosmetic); for global products also assess against EU Eudravigilance, EMA, MHRA YellowCard, MHLW PMDA, etc.
4. Investigate — root cause analysis to support follow-up reporting; for devices, retrieve the device when feasible.
5. Submit — within the regulatory clock to FDA via eMDR / FAERS; mirror to other regulators per their requirements.
6. Follow up — supplementary information as it becomes available; final report when investigation closes.
7. Trend — periodic aggregate analysis to detect signal across reports; feed into PMS and CAPA.

• Confusing the 30-day device MDR clock with the 15-day drug ADR clock — they are different regulations.
• Counting the clock from internal review rather than from "became aware" — the clock starts when anyone in the company learns of the event.
• Treating non-serious malfunctions as non-reportable — for devices, malfunctions that would likely cause or contribute to serious injury if they recurred are reportable.
• Not reporting because causality is uncertain — MedWatch does not require proof; the standard is "reasonably suggests".
• Submitting reports without UDI (devices) — required field; missing it generates eMDR validation rejections.
• Missing the periodic-report cycle while focusing on 15-day alerts.
• Not aligning internal complaint codes with FDA codes (IMDRF terminology for devices; MedDRA for drugs).